[Form 4] Denali Therapeutics Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
Net Seller: 495,282 shares ($7,429,230)
Net Sell
6 txns
Insider
Watts Ryan J.
Role
President and CEO
Sold
495,282 shs ($7.43M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 455,282 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 40,000 | $0.00 | -- |
| Exercise | Common Stock | 455,282 | $0.68 | $310K |
| Exercise | Common Stock | 40,000 | $5.28 | $211K |
| Sale | Common Stock | 495,282 | $15.00 | $7.43M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 622,809 shares (Direct);
Common Stock — 708,353 shares (Direct);
Common Stock — 2,202,604 shares (Indirect, See footnote)
Footnotes (1)
- Includes 177,940 Unvested RSUs. The sales reported by the Reporting Person were made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 09/16/2024. The shares sold primarily relate to 455,282 stock options that expire on 08/21/2025. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. 25% of the shares subject to the option will vest on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.
